CN103154032A - 用于疾病治疗的针对IL-1β和IL-18的抗体 - Google Patents
用于疾病治疗的针对IL-1β和IL-18的抗体 Download PDFInfo
- Publication number
- CN103154032A CN103154032A CN2011800493677A CN201180049367A CN103154032A CN 103154032 A CN103154032 A CN 103154032A CN 2011800493677 A CN2011800493677 A CN 2011800493677A CN 201180049367 A CN201180049367 A CN 201180049367A CN 103154032 A CN103154032 A CN 103154032A
- Authority
- CN
- China
- Prior art keywords
- antibody
- disease
- cell
- conjunction
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37376010P | 2010-08-13 | 2010-08-13 | |
US61/373,760 | 2010-08-13 | ||
PCT/US2011/047532 WO2012021773A1 (en) | 2010-08-13 | 2011-08-12 | Antibodies to il-1beta and il-18, for treatment of disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410753624.0A Division CN104474546A (zh) | 2010-08-13 | 2011-08-12 | 用于疾病治疗的针对IL-1β和IL-18的抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103154032A true CN103154032A (zh) | 2013-06-12 |
Family
ID=44511598
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410753624.0A Pending CN104474546A (zh) | 2010-08-13 | 2011-08-12 | 用于疾病治疗的针对IL-1β和IL-18的抗体 |
CN2011800493677A Pending CN103154032A (zh) | 2010-08-13 | 2011-08-12 | 用于疾病治疗的针对IL-1β和IL-18的抗体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410753624.0A Pending CN104474546A (zh) | 2010-08-13 | 2011-08-12 | 用于疾病治疗的针对IL-1β和IL-18的抗体 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2603525A1 (es) |
JP (1) | JP2013537539A (es) |
KR (1) | KR20130100125A (es) |
CN (2) | CN104474546A (es) |
BR (1) | BR112013003279A2 (es) |
CA (1) | CA2808185A1 (es) |
MX (1) | MX2013001267A (es) |
RU (1) | RU2013110844A (es) |
WO (1) | WO2012021773A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103554264A (zh) * | 2013-11-05 | 2014-02-05 | 哈尔滨博翱生物医药技术开发有限公司 | 针对IL-1β和IL-17A的双特异性抗体及其应用 |
CN110251657A (zh) * | 2019-06-14 | 2019-09-20 | 中山大学 | Ebv brlf1及其功能性小肽在抑制炎症小体活性中的应用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9707235B1 (en) | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
EP3747358A3 (en) | 2013-03-14 | 2021-03-10 | Universite Laval | Use of electroretinography (erg) for the assessment of psychiatric disorders |
KR20160005044A (ko) * | 2013-05-17 | 2016-01-13 | 제넨테크, 인크. | 염증성 장 질환의 진단 및 치료 방법 |
AU2015345321A1 (en) | 2014-11-10 | 2017-04-20 | F. Hoffmann-La Roche Ag | Anti-ANG2 antibodies and methods of use |
EP3218399A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Bispecific antibodies and methods of use in ophthalmology |
CA2963719A1 (en) * | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-il-1beta antibodies and methods of use |
IL301263A (en) * | 2020-11-18 | 2023-05-01 | Novartis Ag | BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY |
JP2023535884A (ja) * | 2021-06-22 | 2023-08-22 | ノバルティス アーゲー | 化膿性汗腺炎の処置における使用のための二特異性抗体 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101062415A (zh) * | 2000-02-21 | 2007-10-31 | 应用研究系统Ars股份公司 | Il-18抑制剂的应用 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US577300A (en) | 1897-02-16 | Printing-press | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4010989A (en) | 1975-10-14 | 1977-03-08 | American Hospital Supply Corporation | Lockable drawer compartment |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
SE8505922D0 (sv) | 1985-12-13 | 1985-12-13 | Kabigen Ab | Construction of an igg binding protein to facilitate downstream processing using protein engineering |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
WO1989012463A1 (en) | 1988-06-21 | 1989-12-28 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU8295491A (en) | 1990-06-29 | 1992-01-23 | Biosource Technologies Incorporated | Melanin production by transformed microorganisms |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
ATE233813T1 (de) | 1991-08-14 | 2003-03-15 | Genentech Inc | Veränderte immunglobuline für spezifische fc- epsilon rezeptoren |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
CA2140933A1 (en) | 1992-08-21 | 1994-02-22 | Paula M. Jardieu | Method for treating an lfa-1 mediated disorder |
DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
ES2108566T3 (es) | 1993-12-10 | 1997-12-16 | Genentech Inc | Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos. |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
EP0739214B1 (en) | 1994-01-18 | 1998-03-18 | Genentech, Inc. | A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS |
CA2181787A1 (en) | 1994-03-03 | 1995-09-08 | Claire M. Doerschuk | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
ATE222774T1 (de) | 1996-01-23 | 2002-09-15 | Genentech Inc | Antikörper gegen cd 18 zur verwendung gegen gehirnschlag |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
AU731817C (en) | 1996-11-27 | 2001-11-01 | Genentech Inc. | Humanized anti-CD11a antibodies |
SI1325932T1 (es) | 1997-04-07 | 2005-08-31 | Genentech Inc | |
CA2288600C (en) | 1997-05-02 | 2010-06-01 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
EP1860187B1 (en) | 1997-05-15 | 2011-07-13 | Genentech, Inc. | Apo-2 receptor |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
SI2319928T1 (sl) | 1998-10-23 | 2013-08-30 | Kirin-Amgen, Inc. | Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
ES2309012T3 (es) | 1999-10-29 | 2008-12-16 | Genentech, Inc. | Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca. |
JP2003531821A (ja) | 1999-12-29 | 2003-10-28 | イムノージェン インコーポレーテッド | 改変型ドキソルビシンおよびダウノルビシンを含む細胞傷害性薬剤ならびにその治療上の使用 |
DK2857516T3 (en) | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
IL153567A0 (en) * | 2000-06-29 | 2003-07-06 | Abbott Lab | Dual specificity antibodies and methods of making and using |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
WO2002051870A2 (en) | 2000-12-22 | 2002-07-04 | GRAD, Carole Legal Representative of KAPLAN, Howard | Phage display libraries of human vh fragments |
EP1921088B1 (en) | 2001-05-11 | 2014-10-08 | Amgen Inc. | Peptides and related molecules that bind to tall-1 |
WO2004081026A2 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Polypeptides |
US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
KR101438983B1 (ko) | 2003-11-06 | 2014-09-05 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
BRPI0615026A8 (pt) | 2005-08-19 | 2018-03-06 | Abbott Lab | imunoglobulina de domínio variável duplo e seus usos |
US20090298764A1 (en) * | 2006-03-15 | 2009-12-03 | Regents Of The University Of Colorado | Gene and pathway and their use in methods and compositions for predicting onset or progression of autoimmune and/or autoinflammatory diseases |
RU2008144802A (ru) * | 2006-04-14 | 2010-05-20 | Новартис АГ (CH) | Применение антител против ил-1 для лечения глазных расстройств |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
CA3156905C (en) * | 2007-05-29 | 2023-11-07 | Novartis Ag | New indications for anti-il-i-beta therapy |
US20090202557A1 (en) * | 2008-01-30 | 2009-08-13 | Argiriadi Maria A | Compositions and methods for crystallizing antibody fragments |
WO2010028275A1 (en) * | 2008-09-05 | 2010-03-11 | Xoma Technology Ltd. | METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES |
-
2011
- 2011-08-12 EP EP11748847.8A patent/EP2603525A1/en not_active Withdrawn
- 2011-08-12 CN CN201410753624.0A patent/CN104474546A/zh active Pending
- 2011-08-12 CN CN2011800493677A patent/CN103154032A/zh active Pending
- 2011-08-12 MX MX2013001267A patent/MX2013001267A/es not_active Application Discontinuation
- 2011-08-12 BR BR112013003279A patent/BR112013003279A2/pt not_active IP Right Cessation
- 2011-08-12 RU RU2013110844/10A patent/RU2013110844A/ru not_active Application Discontinuation
- 2011-08-12 KR KR1020137006238A patent/KR20130100125A/ko not_active Application Discontinuation
- 2011-08-12 CA CA2808185A patent/CA2808185A1/en not_active Abandoned
- 2011-08-12 JP JP2013524239A patent/JP2013537539A/ja active Pending
- 2011-08-12 WO PCT/US2011/047532 patent/WO2012021773A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101062415A (zh) * | 2000-02-21 | 2007-10-31 | 应用研究系统Ars股份公司 | Il-18抑制剂的应用 |
Non-Patent Citations (3)
Title |
---|
FLAKSMAN等: "NOD2 investigating IBD with autophagy and interleukins", 《EUKARYON.》, vol. 6, 31 March 2010 (2010-03-31) * |
SAITOH T等: "Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production.", 《NATURE》, vol. 456, no. 7219, 13 November 2008 (2008-11-13), pages 264 - 8 * |
袁育红 等: "细胞因子与炎症性肠病", 《中国胃肠外科杂志》, vol. 2, no. 4, 31 December 1999 (1999-12-31), pages 251 - 254 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103554264A (zh) * | 2013-11-05 | 2014-02-05 | 哈尔滨博翱生物医药技术开发有限公司 | 针对IL-1β和IL-17A的双特异性抗体及其应用 |
CN110251657A (zh) * | 2019-06-14 | 2019-09-20 | 中山大学 | Ebv brlf1及其功能性小肽在抑制炎症小体活性中的应用 |
Also Published As
Publication number | Publication date |
---|---|
MX2013001267A (es) | 2013-04-10 |
WO2012021773A1 (en) | 2012-02-16 |
RU2013110844A (ru) | 2014-09-20 |
CA2808185A1 (en) | 2012-02-16 |
BR112013003279A2 (pt) | 2016-06-14 |
CN104474546A (zh) | 2015-04-01 |
JP2013537539A (ja) | 2013-10-03 |
EP2603525A1 (en) | 2013-06-19 |
KR20130100125A (ko) | 2013-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230143310A1 (en) | Anti-pd1 antibodies and methods of use | |
US20220363755A1 (en) | Anti-tim3 antibodies and methods of use | |
CN103154032A (zh) | 用于疾病治疗的针对IL-1β和IL-18的抗体 | |
ES2744540T3 (es) | Anticuerpos anti-CD79b y procedimientos de uso | |
AU2022231722A1 (en) | Humanized and affinity matured antibodies to FcRH5 and methods of use | |
CN101809034B (zh) | C3b抗体及用于预防和治疗补体相关病症的方法 | |
JP2022174169A (ja) | 抗bcma重鎖のみ抗体 | |
CN108137699A (zh) | 对pd1和tim3特异性的双特异性抗体 | |
US20130287766A1 (en) | Antibodies and methods for making and using them | |
KR20190117489A (ko) | 항-bcma 중쇄-단독 항체 | |
CN106459201A (zh) | 结合人和食蟹猴CD3ε的抗体 | |
JP2002530081A (ja) | 親抗体より高度な結合親和性を持つ抗体変異体 | |
IL181186A (en) | COMPOSITION USEFUL FOR DOWNREGULATING Fc-EPSILON-RI ACTIVITY COMPRISING A BISPECIFIC ANTIBODY OR POLYPEPTIDE THAT CROSSLINKS AN Fc-GAMMA-RIIB RECEPTOR WITH AN Fc-EPSILON-RI-ALPHA- RECEPTOR | |
CN105949313A (zh) | 抗体Fc变体 | |
CN107074941A (zh) | 双特异性抗体和用于眼科学的方法 | |
CN107074942A (zh) | 抗‑IL‑1β抗体和使用方法 | |
CN103917556A (zh) | 抗HtrA1抗体及使用方法 | |
CN103890006A (zh) | 抗mcsp抗体 | |
CN110494453A (zh) | 抗类胰蛋白酶抗体、其组合物及其用途 | |
CN107148429A (zh) | 抗‑pdgf‑b抗体和使用方法 | |
US20150274833A1 (en) | Recombinant bispecific antibody binding to cd20 and cd95 | |
CN104520328A (zh) | 抗锯齿蛋白抗体及使用方法 | |
JP2020513761A (ja) | 抗il−5抗体 | |
WO2023002952A1 (en) | Protease-mediated target specific cytokine delivery using fusion polypeptide | |
US20130149308A1 (en) | Antibodies to il-1beta and il-18, for treatment of disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1186194 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130612 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1186194 Country of ref document: HK |